Prostatic hyperplasia treatment
Dutasteride (Avodart™) is part of a group of medicines referred to as 5-alpha reductase type I & II inhibitors. It prevents the 5-alpha reductase type I & II enzyme of converting testosterone into its active form within the organism, dihydrotestosterone or DHT. DHT plays an important role in hereditary baldness in men (androgenetic alopecia). The 5-alpha reductase type I & II enzyme is found in higher concentration at the hair follicles of men suffering from androgenetic alopecia.
Dutasteride (Avodart™) is developed in 0,5-mg/day doses by the pharmaceutical company "GlaxoSmithKline" and is FDA approved (U.S. Food and Drug Administration) for treating prostatic hyperplasia under the brand name Avodart™ (reference : 21-319/S-001). At present Dutasteride has not been approved for treating androgenetic alopecia.
The immediate side effects of Dustasteride are considerable and not well known on long-term scope.